南方财经全媒体记者杨雨莱 广州报道
On October 9th, Guangdong province issued the "Action Plan for Further Promoting the High-Quality Development of the Guangdong’s Biotech and Pharma Industry"("Action Plan").
Action Plan is focusing on various aspects of innovation mechanisms, product enhancement, industry clustering, and environment promotion, which addresses 38 key measures.
How to promote the high-quality development of the biopharmaceutical industry in Guangdong? Two key forces are required.
Firstly, to promote the hard power of internal development capabilities. It requires self-cultivation of domestic enterprises. Guangdong will select a batch of high-quality biopharmaceutical companies for cultivation, creating more leading companies, single-champion enterprises, and specialized, refined, and innovative enterprises, promoting the integrated development of large, medium, and small enterprises.
The Action Plan points out that by 2027, Guangdong will cultivate and develop no less than 15 enterprises at the level of tens of billions.
Secondly, it is necessary to build the cohesive force for external development. It is essential to fully leverage Guangdong's vast market potential and effectively use the Hong Kong and Macao Medicine and Equipment Connect policy. Focus on key enterprises for one-on-one docking, accelerate the introduction of leading companies, high-end R&D institutions, and significant industrial projects in the domestic and international biopharmaceutical fields, and promote the transformation and landing of more innovative drugs and devices in Guangdong.
In terms of cluster construction and services, large-scale industrial agglomeration areas and provincial-level industrial parks will be utilized to support policies and measures, promoting the formation of more than 10 biopharmaceutical industrial parks with distinctive features, significant scale and benefits, and obvious radiation and driving effects.
The Action Plan clarifies that by 2027, Guangdong province aims to achieve the size of biotech and healthcare industry cluster over one trillion yuan.
A representative of Shenzhen Chipscreen Biosciences Company expressed to SFC journalist that the Action Plan promotes the conduct of clinical experiments of innovative drugs and devices by public hospitals, which can give full play to the advantages of Guangdong's medical resources and accelerate the collaborative transformation of corporate innovation achievements.
策划：于晓娜
监制：施诗
责任编辑：和佳
记者：杨雨莱
摄制：李群
新媒体统筹：丁青云 曾婷芳 赖禧 黄达迅
海外运营监制: 黄燕淑
海外运营内容统筹: 黄子豪
海外运营编辑：庄欢 吴婉婕 龙李华 张伟韬
出品：南方财经全媒体集团
